Introduction
Lenor 2.5 mg (Letrozole) Tablet is a nonsteroidal aromatase inhibitor designed for the first-line treatment of advanced or metastatic hormone receptor-positive breast cancer in postmenopausal women. Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified leader in oncology therapeutics, and supplied globally by Onco Solution, this targeted therapy suppresses estrogen production to starve hormone-dependent tumors. Lenor 2.5 mg (Letrozole) Tablet offers a clinically proven, well-tolerated option for managing estrogen-sensitive breast cancer with minimal impact on adrenal function.
Key Benefits & Mechanism of Action
Lenor 2.5 mg (Letrozole) Tablet works by irreversibly inhibiting aromatase, the enzyme responsible for converting androgens to estrogens. Key mechanisms include:
- Estrogen Suppression: Reduces serum estrogen levels (estrone, estradiol) by 75–95%, depriving cancer cells of growth stimuli.
- Selective Action: Does not affect adrenal corticosteroid, aldosterone, or thyroid hormone synthesis.
- Nonsteroidal Inhibition: Competitively binds to the cytochrome P450 subunit of aromatase, ensuring targeted action without hormonal disruption.
Indications
Lenor 2.5 mg (Letrozole) Tablet is approved for:
- Advanced/Metastatic Breast Cancer: First-line therapy for postmenopausal women with hormone receptor-positive or unknown-status tumors.
Dosage & Administration
- Recommended Dose: 2.5 mg once daily, with or without food.
- Treatment Duration: Continue until tumor progression or unacceptable toxicity.
- Special Populations:
- Hepatic Impairment: Reduce dose to 2.5 mg every other day in severe hepatic dysfunction.
- Renal Impairment: No adjustment needed for creatinine clearance ≥10 mL/min.
- Elderly Patients: No dose modification required.
Pharmacokinetics
- Absorption: 99.9% bioavailability; peak plasma concentration in 2 hours (delayed slightly by food).
- Metabolism: Primarily metabolized to an inactive carbinol metabolite via CYP3A4 and CYP2A6.
- Excretion: Half-life of ~48 hours; steady-state levels achieved in 2–6 weeks.
- Protein Binding: 60% (mainly albumin).
Side Effects
Common Reactions
- Musculoskeletal: Pain (30%), arthralgia (20%).
- Vasomotor: Hot flashes (25%).
- Gastrointestinal: Nausea (15%), fatigue (10%).
- Dermatologic: Hair thinning, rash.
Serious but Rare
- Osteoporosis, dizziness, elevated liver enzymes.
Contraindications
- Hypersensitivity to letrozole or aromatase inhibitors.
- Pregnancy, lactation, or premenopausal status.
- Severe hepatic dysfunction.
Drug Interactions
- CYP3A4 Inducers/Inhibitors: Minimal clinical impact (e.g., cimetidine, warfarin).
- Tamoxifen: Avoid concurrent use (reduces letrozole efficacy).
Precautions & Warnings
- Hepatic Monitoring: Monitor liver function in moderate hepatic impairment.
- Bone Health: Assess bone density periodically due to estrogen suppression.
- Machinery Use: Advise caution due to fatigue/dizziness.
Pregnancy & Lactation
- Pregnancy Category D: Fetal harm observed in animal studies. Contraindicated in pregnancy.
- Lactation: Avoid breastfeeding; excretion in human milk unknown.
Overdose Management
No specific antidote. Supportive care includes emesis (if alert), dialysis (weak protein binding), and monitoring vital signs.
Storage & Handling
Store below 30°C in original packaging, away from light and moisture. Keep out of children’s reach.
Manufacturer & Supplier
Eskayef Pharmaceuticals Ltd., a pioneer in oncology innovation since 1990, produces Lenor 2.5 mg (Letrozole) Tablet in WHO-GMP-certified facilities, ensuring global compliance and affordability. Onco Solution, a trusted global supplier, delivers this therapy to 50+ countries, offering bulk procurement and clinical support via www.oncosolution.com.
Conclusion
Lenor 2.5 mg (Letrozole) Tablet is a cornerstone of hormonal therapy for postmenopausal breast cancer, combining targeted efficacy with a favorable safety profile. Trust Eskayef Pharmaceuticals Ltd. for quality and Onco Solution for reliable global access. For orders or clinical guidance, contact Onco Solution today.
